Free Trial

UroGen Pharma (NASDAQ:URGN) Earns "Buy" Rating from D. Boral Capital

UroGen Pharma logo with Medical background
Remove Ads

D. Boral Capital restated their buy rating on shares of UroGen Pharma (NASDAQ:URGN - Free Report) in a report issued on Monday morning,Benzinga reports. The firm currently has a $25.00 target price on the stock.

URGN has been the subject of several other research reports. LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They issued a "buy" rating and a $31.00 price target for the company. HC Wainwright restated a "buy" rating and set a $64.00 target price on shares of UroGen Pharma in a report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $38.20.

Get Our Latest Analysis on URGN

UroGen Pharma Trading Up 0.7 %

Shares of NASDAQ:URGN traded up $0.08 during trading on Monday, reaching $10.90. 222,570 shares of the company were exchanged, compared to its average volume of 377,910. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The firm has a market capitalization of $255.65 million, a PE ratio of -3.46 and a beta of 1.12. The business's fifty day simple moving average is $10.45 and its 200-day simple moving average is $11.70. UroGen Pharma has a 12-month low of $9.03 and a 12-month high of $20.70.

Remove Ads

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings results on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The firm had revenue of $24.57 million during the quarter, compared to analyst estimates of $25.25 million. On average, research analysts anticipate that UroGen Pharma will post -3.12 EPS for the current year.

Insider Activity at UroGen Pharma

In other news, General Counsel Jason Drew Smith sold 7,379 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now owns 26,468 shares in the company, valued at approximately $294,853.52. This represents a 21.80 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of the firm's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the sale, the insider now directly owns 145,666 shares of the company's stock, valued at $1,622,719.24. The trade was a 3.03 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On UroGen Pharma

Several hedge funds have recently modified their holdings of the stock. KLP Kapitalforvaltning AS purchased a new stake in UroGen Pharma during the 4th quarter worth approximately $59,000. Lazard Asset Management LLC acquired a new stake in shares of UroGen Pharma during the fourth quarter worth $67,000. BNP Paribas Financial Markets grew its holdings in shares of UroGen Pharma by 221.8% during the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company's stock valued at $109,000 after buying an additional 5,890 shares during the last quarter. Aquatic Capital Management LLC acquired a new position in shares of UroGen Pharma in the 4th quarter valued at $101,000. Finally, Oppenheimer & Co. Inc. acquired a new stake in UroGen Pharma during the 4th quarter worth about $126,000. Institutional investors and hedge funds own 91.29% of the company's stock.

UroGen Pharma Company Profile

(Get Free Report)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

Featured Articles

Analyst Recommendations for UroGen Pharma (NASDAQ:URGN)

Should You Invest $1,000 in UroGen Pharma Right Now?

Before you consider UroGen Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.

While UroGen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

7 Flying Car Stocks to Buy Before the Sector Really Takes Off

7 Flying Car Stocks to Buy Before the Sector Really Takes Off

Flying cars are coming sooner than you think! Investors are getting excited about this futuristic industry, and MarketBeat analyst Chris Markoch breaks down 7 flying car stocks poised to take off.

Related Videos

Archer Aviation: Sinking Now, Soaring Soon?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
Palantir’s Explosive Growth: Buy Now or Wait for a Dip?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads